AbbVie: RINVOQ Meets Primary Endpoints In Phase 3 Studies :

WASHINGTON (dpa-AFX) - AbbVie (ABBV) reported positive top-line results from the first of two studies of the phase 3 SELECT-AXIS 2 clinical trial evaluating RINVOQ in patients with active ankylosing

Related Keywords

Washington , United States , , Abbvie , Rinvoq , Meets , Primary , Endpoints , Hase , Studies ,